Posted by AGORACOM-JC
at 7:54 AM on Thursday, April 1st, 2021
ImagineAR Selections Include Sinclair Broadcast Group, Rogers Sports & Media, Vegas Knights, Philadelphia Phillies, Minnesota Vikings
Announced that thirteen different Sports Teams, Federations and Media Broadcasters selected ImagineAR during the Hype Sports Innovation Draft Day on March 31, 2021
HYPE Sports Innovation has built the largest global ecosystem in sports innovation.
With over 40,000 members, including retail brands, athletic clubs, federations and academia together with over 11,000 startups, HYPE has an unrivalled capacity for outreach to global partners across all sectors in this highly diverse field.
VANCOUVER, BC and ERIE, Pa. , April 1, 2021 – Imagine AR Inc. (CSE: IP) (OTCQB: IPNFF) (“ImagineAR” or “Company”) an Augmented Reality Company that enables sports teams, businesses and enterprises to instantly create their own AR mobile campaigns, is pleased to announce that thirteen different Sports Teams, Federations and Media Broadcasters selected ImagineAR during the Hype Sports Innovation Draft Day on March 31, 2021 .
“Today’s Hype Sports Innovation Draft Day was a historic event for the stakeholders of ImagineAR that goes beyond the selection of 13 rights holders representing a worldwide list of sports federations, teams, and media broadcast groups,” said Neal Bendesky , ImagineAR’s VP of Sports. “We are appreciative to Ryan McCumber and the Hype team for offering this unique opportunity for emerging start-ups to help these partners to adjust and innovate after the pandemic. Our augmented reality platform is an effective tool to assist the sports, music, retail and entertainment industries imagine and adapt to blaze a new trail for their business models. Thanks to Hype, we can now grow our brand and activate AR solutions for worldwide clients including:”
NFL: Minnesota Vikings MLB: Philadelphia Phillies NHL: St. Louis Blues , Vegas Golden Knights World Governing Body of Cricket: International Cricket Council (ICC) World Governing Body of Football: Deutscher Fußball-Bund (DFB) Bundesliga: 1. FC Koln Leading provider of Local Sports & News ( USA ): Sinclair Broadcast Group Leading provider Mass Media & Sports Properties ( Canada ): Rogers Sports & Media Serie A (Top flight of Italian Football): Bologna FC Uruguayan Primera Division: C.FdeF MLS & USL: Inter Miami Categoria Primera A: Atletico Nacional
HYPE Sports Innovation has built the largest global ecosystem in sports innovation. With over 40,000 members, including retail brands, athletic clubs, federations and academia together with over 11,000 startups, HYPE has an unrivalled capacity for outreach to global partners across all sectors in this highly diverse field.
GrubHub WebAR Live Streaming Concert with Megan Thee Stallion (Billboard March 29, 2021 )
As per the Billboard Article published on March 29, 2021 , ‘ Megan Thee Stallion , Noah Cyrus and King Princess Take Over GrubHub Sound Bites Interactive Concert’ , Noah Cyrus , King Princess and Megan Thee Stallion came together for GrubHub Sound Bites’s first-ever immersive AR livestream concert. The free event, which virtually took place on March 26 , honored Women’s History Month and World Central Kitchen.
As part of the ImagineAR experience, fans were encouraged to scan customized QR codes that appeared throughout the show to receive special discounts and perks. Those included a chance to win a meet-and-greet with each artist, seeing behind-the-scenes footage, winning a $5 perk to place orders and chances to win a GrubHub gift card.
Within the first 48 hours following the livestream, over 10 million viewers have engaged with the content while driving over 160k interactions from the QR’s scan engagement.
“This was ImagineAR’s first successful WebAR event for First Tube Media and probably the biggest music live streaming WebAR event in history” according to Alen Paul Silverrstieen, CEO of ImagineAR.
ImagineAR Issues Stock Options to Directors and Officers
Imagine AR announces that on April 1, 2021 the Company granted 1,500,000 stock options to directors and officers of the Company. These stock options are granted in accordance with the terms of the stock option plan of ImagineAR Inc. The options will vest 50% on the date of grant with the remainder vesting in 90 days and each option entitles the holder thereof to purchase one (1) common share of ImagineAR Inc. at a price of $0.41 per common share for a period of three (3) year.
Posted by AGORACOM-JC
at 10:45 PM on Wednesday, March 31st, 2021
Revenues of $17,775,029, an increase of 269% over $4,813,978 posted in the prior year,
Net earnings and comprehensive income of $41,768,404 an increase of $50,939,521 over 2019,
Net earnings and comprehensive income from operations (before share-based expenses) of $2.9MM during fiscal year 2020 vs ($7.9MM) posted over the same period in 2019,
Gross margin of 58%, an increase of 21% year over year,
Cash and cash equivalents at December 31, 2020 of $18,104,899 (December 31, 2019: $34,431),
Backlog of signed contracts of $30MM,
Basic Earnings per Share (EPS) of $0.28 for 2020 as compared to ($0.07) in 2019,
Total Assets at December 31, 2020 of $74.5MM (December 31, 2019: $9.6MM),
Shareholders’ Equity at December 31, 2020 of $59.4MM (December 31, 2019: ($6.1MM)).
MONTREAL, March 31, 2021 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (NASDAQ: PYR) (FRA:8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, environmentally friendly plasma waste-to-energy systems and clean plasma torch products, is pleased to announce today its financial and operational results for the fourth quarter and fiscal year ended December 31 st , 2020.
“We are happy to announce Q4, and fiscal year end, results for the period ending December 31 st , 2020, which continue the historical trends began earlier in the year. Our full year revenues of $18MM reflects the successful processing of backlog from signed contracts previously disclosed. The Board’s choice of strategy has been validated with the reporting of the second profitable quarter in a row. Further validating this strategy, net income from operations (before share-based expenses) was $3.3MM for the year which is quite significant given the uncertain environment that 2020 was, and during which the Company not only retired virtually all of its debt, but also uplisted to the Toronto Stock Exchange and positioned itself for a NASDAQ listing in Q1 2021,” said Mr. P. Peter Pascali, CEO and Chair of PyroGenesis. “The successes of 2020, when combined with the results from our strategic investment, have contributed to a basic EPS of $0.16 for the quarter, and $0.28 for the year, both of which have exceeded previous guidance. With a strong balance sheet and approx. $27MM of cash-on-hand as at this writing, the Company is well positioned to execute on its strategy of growth and solidify its position as an emerging leader in the reduction of greenhouse gas emissions, and as such, we expect these trends established in 2020 to continue.”
2020 results reflect the following highlights:
Revenues of $17,775,029, an increase of 269% over $4,813,978 posted in the prior year,
Net earnings and comprehensive income of $41,768,404 an increase of $50,939,521 over 2019,
Net earnings and comprehensive income from operations (before share-based expenses) of $2.9MM during fiscal year 2020 vs ($7.9MM) posted over the same period in 2019,
Gross margin of 58%, an increase of 21% year over year,
Cash and cash equivalents at December 31, 2020 of $18,104,899 (December 31, 2019: $34,431),
Backlog of signed contracts of $30MM,
Basic Earnings per Share (EPS) of $0.28 for 2020 as compared to ($0.07) in 2019,
Total Assets at December 31, 2020 of $74.5MM (December 31, 2019: $9.6MM),
Shareholders’ Equity at December 31, 2020 of $59.4MM (December 31, 2019: ($6.1MM)).
OUTLOOK
Given the success over the last 18 months, PyroGenesis is well positioned, with a clean balance sheet, and approx. $27 million cash-on-hand (as of this writing), to execute on all its organic growth strategies as well as actively pursuing growth through synergistic merger and acquisitions.
PyroGenesis has recently focused, and repositioned its offerings, to highlight the GHG emissions reduction benefits associated with the majority of its products. Interestingly enough, PyroGenesis’ product lines do not generally need to incorporate GHG/environmental benefits to make sense economically. In other words, they do not require GHG/environmental incentives (tax credits GHG certificates, environmental subsidies) to make sense from a business perspective. We believe these incentives will be a tailwind that will add directly to shareholder value.
We consider this repositioning to be timely as many governments around the world are considering stimulating their respective economies by promoting environmental technologies. As such, Management expects that this repositioning will result in increased revenues.
Organic Growth:
Organic growth will be spurred on by (i) the natural growth of our existing offerings which can now be accelerated given our strong balance sheet and (ii) leveraging off our “Golden Ticket” advantage.
We have described in the past our Golden Ticket advantage as one which occurs when one sells directly, or is engaged directly, with the end user and, as a result, is “inside the fence”. A Golden Ticket affords the opportunity to either, (i) cross sell other products or, ideally, (ii) identify new areas of concern that can be addressed uniquely by PyroGenesis. We call the latter our Coffee and Donuts strategy (if you are selling coffee you could generate additional revenues, with little additional effort, by adding on donuts).
Over the past several years, PyroGenesis has successfully positioned each of its business lines for rapid growth by strategically partnering with multi-billion-dollar entities. These entities have identified PyroGenesis’ offerings to be unique, in demand, and of such a commercial nature as to warrant such unique relationships. We expect that these relationships are now positioned to transition into significant revenue streams.
DROSRITE™
Within the DROSRITE™ offering, the Company is aggressively exploring horizontal growth opportunities. The Company is currently bidding on an RFQ, valued at approx. $40MM (estimated award date: within 4 months; estimated time to completion: approx. 15 months). Management notes that it has been very successful in the selection process to date, but does not yet consider it to be a high-probability outcome at this stage, and provides such as an example of its commitment to this strategy.
Additive Manufacturing
With respect to our Additive manufacturing offering, we expect to see significant year over year improvements in our 3D metal powders offering as our production kicks into gear by incorporating all the previously disclosed benefits (increased production rates, lower capex, lower opex) locked into our production line. There are major top tier aerospace companies and OEMs in both Europe and North America eagerly awaiting powders from this new state of the art production line. Whereas in the past we have been primarily targeting the very demanding Aerospace industry, we have recently expanded the target market to also address the unique needs of the electric vehicles marketplace who have recently approached us with their powder needs.
Plasma Torches
With respect to the Company’s plasma torch offerings, we expect this offering to be significantly impacted by continued developments in the iron ore pelletization industry, where serious consideration is being given to replacing the fossil fuel burners, currently being used throughout the industry, with PyroGenesis’ proprietary plasma torches, in an effort to reduce their carbon footprint.
To date, everything is proceeding as expected. Initial discussions have evolved into confirmation stages which typically consist of a computer simulation followed by a small torch order. These confirmation stages are expected, if successful, to result with a roll-out program to replace fossil fuel burners with PyroGenesis’ plasma torches in the iron ore pelletization industry, in which PyroGenesis is patent protected.
PyroGenesis is proactively targeting other industries which are experiencing significant pressure to reduce GHGs, and which utilize fossil fuel burners as well.
Separately, the Company also offers plasma torches to niche markets where there is a high probability of on-going sales from successful implementation. One such example is the previously announced contract with a small company to produce a plasma torch ideal for tunnelling. PyroGenesis is currently re-evaluating its relationship with respect to this opportunity as there may be evidence that the real plasma-based tunnelling opportunity could lie outside of the scope of the current agreement.
As sales of PyroGenesis’ plasma torches increase, the Company will also benefit from providing proprietary spare parts from which the Company expects to generate significant recurring revenue, thus complementing the Company’s long-term strategy to build upon a recuring revenue model.
HPQ/PUREVAP™
With respect to HPQ, the goal is expanding our role as HPQ technology provider for the game changing PUREVAP™ family of silicon processes which we are developing exclusively for HPQ and its wholly owned subsidiary HPQ Nano Silicon Powders Inc, namely:
The PUREVAP™ “Quartz Reduction Reactors” (QRR), an innovative process (patent pending), which should permit the one step transformation of lower purity quartz (SiO2) than any traditional processes can handle into a silicon (Si) of a higher purity level (2N-4N) that can be produced by any traditional smelter, at reduced costs, energy input, and carbon footprint. The unique capabilities of this process could position HPQ as a leading provider of the specialized silicon material needed to propagate its considerable renewable energy potential; and
The PUREVAP™ Nano Silicon Reactor (NSiR), which, if successful, could position itself as a new proprietary low-cost process that can transform the silicon (Si) made by the PUREVAP™ QRR into the nano-silicon materials (spherical silicon powders and silicon nanowires) sought after by energy storage, batteries, electric vehicle manufactures and clean hydrogen sectors participants. The aim of the ongoing work is to position HPQ NANO as the first to market with a commercial scale low-cost nanoparticle production system.
We expect 2021 to be a year in which significant development occurs on both these fronts.
Growth through Synergistic Mergers and Acquisitions:
As previously disclosed, the Company would conservatively consider a synergistic M&A strategy to augment its growth, and the Company has been very actively involved in pursuing several opportunities in support of this strategy. In so doing, the focus has been on private companies exclusively which (i) primarily leverage the Company’s Golden Ticket advantage/Coffee & Donuts strategy or (ii) could uniquely benefit from the Company’s engineering advantage and/or international relationships.
The Company expects to be announcing specific details over the next few weeks as these opportunities become more binding on the parties involved.
DROSRITE™
We expect to be able to announce within the next several weeks, the conclusion of a joint venture relationship with an existing and proven technology provider. The technology is geared to uniquely handle the residues resulting from the processing of dross in the aluminum industry. We had previously announced our intention to secure this technology and, if concluded, would not only make our traditional DROSRITE™ offering more appealing but could also be offered as a stand-alone product. We believe that valorizing the residues and producing high end products will further define us as the go-to company for all dross related processing. This is a prime example of our Coffee & Donuts strategy in play. For further clarity, the joint venture will only relate to the new technology and, as such, PyroGenesis will not have to vet in any assets, or IP (specifically not the DROSRITE™ technology).
Plasma Torches
PyroGenesis often considers opportunities to leverage its plasma expertise and has been reviewing a torch technology which could complement PyroGenesis’ existing offerings, and leverage off of our unique relationships. The Company gives this a very low probability of success given the initial valuation, provided by the sole owner, in the context of publicly available data. However, PyroGenesis has identified similar opportunities and will evaluate them in due course.
Complimentary
The Company expects to announce in the next several weeks details regarding its intent to enter the Renewable Natural Gas (RNG) market via acquisition. PyroGenesis believes that it is in a unique position to take advantage of the lack of sufficient players (given anticipated demand) in the RNG marketplace by leveraging its engineering capabilities & existing relationships.
In conclusion, PyroGenesis is well positioned in 2021 to take advantage of its unique position in its four main business offerings to accelerate growth in each, with a particular emphasis on offerings geared to aggressively reducing GHG emissions. Furthermore, we do not expect at this point in time, given our strong balance sheet, a need to raise capital to execute on our growth strategy over the foreseeable future.
Financial Summary
Revenues
PyroGenesis recorded revenues of $17,775,029 for the year ended December 31, 2020, representing an increase of 269% compared to $4,813,978 recorded in 2019.
Revenues recorded in fiscal 2020 were generated primarily from:
(i)
PUREVAP™ related sales of $4,163,059 (2019 – $525,556)
(ii)
DROSRITE™ related sales of $9,976,696 (2019 – $560,916)
(iii)
support services related to systems supplied to the US Military $1,425,883 (2019 – $637,841)
(iv)
torch related sales of $1,452,455 (2019 – $2,323,351)
(v)
other sales and services $756,936 (2019 – $766,314)
PUREVAP™ related sales includes revenue from the sale of technologies in the amount of $3,610,000.
Cost of Sales and Services and Gross Margins
Cost of sales and services before amortization of intangible assets was $7,445,171 in 2020, representing an increase of 113% compared to $3,495,753 in 2019, primarily due to an increase in subcontracting, direct materials, an increase in foreign exchange charge on materials offset by a decrease in employee compensation, and investment tax credits.
In 2020, employee compensation, manufacturing overhead & other decreased to $1,886,854 (2019 – $2,230,361). Of note, the Company in 2020 applied for an amount of $775,967 in wage subsidy from Revenue Canada under the CEWS “Canada Emergency Wage Subsidy” program. From this amount, $118,416 was applied to employee compensation under cost of sales and services. Subcontracting and direct materials increased to $5,429,175 (2019 – $1,471,226), primarily due to the increased amount of contract values.
The gross margin for 2020 was $10,302,668 or 58% of revenue compared to a gross margin of $1,298,092 or 27% of revenue for 2019. As a result of the type of contracts being executed, the nature of the project activity had a significant impact on the gross margin and the overall level of cost of sales and services reported in a period, as well as the composition of the cost of sales and services, as the mix between labour, materials and subcontracts may be significantly different. The cost of sales and services for 2020 and 2019 are in line with Management’s expectations. The gross margin includes the full effect of the sale of intellectual property and royalties of $3,610,000 in 2020. Excluding the effect of this revenue, the gross margin for 2020 would have been 47.2%.
Investment tax credits recorded against cost of sales are related to projects that qualify for tax credits from the provincial government of Quebec. Qualifying tax credits decreased to $18,420 in 2020, compared to $179,670 in 2019. The decrease is primarily related to fewer contracts being eligible for qualifying tax credits.
The amortization of intangible assets of $27,190 in 2020 and $20,133 for 2019 relates to patents and deferred development costs. Of note, these expenses are non-cash items and will be amortized over the duration of the patent lives.
Selling, General and Administrative Expenses
Included within Selling, General and Administrative expenses (“SG&A”) are costs associated with corporate administration, business development, project proposals, operations administration, investor relations and employee training.
SG&A expenses for 2020 excluding the costs associated with share-based compensation (a non-cash item in which options vest principally over a four-year period), were $8,089,945, representing an increase of 34% compared to $6,017,091 reported for 2019.
The increase in SG&A expenses in 2020 over the same period in 2019 is mainly attributable to the net effect of:
(i)
an increase of 79% in employee compensation primarily due to additional head count, an increase in commissions, bonuses, offset by an amount of $504,339 received from Revenue Canada under the CEWS program.
(ii)
an increase of 14% for professional fees, primarily due to an increase in legal fees, public listing fees and patent expenses,
(iii)
an increase of 12% in office and general expenses, is primarily due to computer, internet, and security expenses,
(iv)
travel costs decreased by 71%, due to a decrease in travel abroad,
(v)
depreciation on property and equipment decreased by 63% due to lower amounts of property and equipment being depreciated,
(vi)
depreciation on right of use assets increased by 13% due to higher amounts of right of use assets being depreciated,
(vii)
investment tax credits were almost the same year to year, and include the recognition of investment tax credits in the amount of $30,000,
(viii)
government grants decreased by 4%, due to lower levels of activities supported by such grants,
(ix)
other expenses decreased by 8%, primarily due to an increase in advertising, interest and bank expenses,
(x)
the tax assessment in 2019, represents the amount due from a taxation audit for the period of 2008 to 2011. The Company paid royalties for the use of intangible property prior to the purchase of the asset. The royalties were subject to a 25% withholding tax that was not deducted or withheld by the Company at that time.
Separately, share based payments increased by $4,072,801 in 2020 over the same period in 2019 as a result of the stock options granted on July 16, 2020. This was directly impacted by the vesting structure of the stock option plan with options vesting between 25% and 50% on the grant date requiring an immediate recognition of that cost.
Research and Development (“R&D”) Costs
The Company incurred $775,824 of R&D costs less $1,033,412 of investment tax credits which reduce income taxes payable in current year less $24,605 of investment tax credit refund from previous year, less $83,451 of 2020 eligible investment tax credits, less government grants of $365,433 totaling a net R&D cost of ($731,077), on internal projects in 2020, a decrease of 186% compared to $851,512 in 2019. The decrease in 2020 is primarily related to an increase of labor resources allocated to non research and development contracts.
In addition to internally funded R&D projects, the Company also incurred R&D expenditures during the execution of client funded projects. These expenses are eligible for Scientific Research and experimental Development (“SR&ED”) tax credits. SR&ED tax credits on client funded projects are applied against cost of sales and services (see “Cost of Sales” above).
Net Finance Costs
Finance costs for 2020 totaled $524,074 as compared with $1,237,504 for 2019, representing a decrease of 58% year-over-year. The decrease in finance costs, is primarily attributable to the extinguishment of all term loans, other loans, and convertible debentures in 2020.
Strategic Investments
The adjustment to the fair market value of strategic investments in 2020 resulted in a gain of $44,626,698 compared to a gain in the amount of $176,237 in 2019, representing an increase of $44,450,461. The increase is primarily attributable to the increased market share value of common shares and warrants owned by the Company of HPQ Silicon Resources Inc.
Net Earnings and Comprehensive Income (Loss)
(i)
an increase in product and service-related revenue of $12,961,051 arising in 2020,
(ii)
an increase in cost of sales and services totaling $3,956,475, primarily due to higher subcontract costs, and direct materials as a result of an increase in contracts in 2020,
(iii)
an increase in SG&A expenses not including share-based expenses of $2,072,854 arising in 2020 primarily due an increase in employee commissions and bonuses,
(iv)
a decrease in R&D expenses of $1,582,589 primarily related the recognition of investment tax credits in 2020 and prior years in the amount of $1,141,468 which include amounts that reduce Canadian income taxes payable in 2020 and an amount of $365,433 in government grants,
(v)
a decrease of $1,981,410 in 2020 due to impairment of a Plasma Atomization 2019. The Company commenced construction on a new and improved Plasma Powder Production equipment,
(vi)
a decrease of $386,121 in 2020 due to the write off, of powders and raw materials inventory in 2019,
(vii)
an increase in share-based expense of $4,072,801,
(viii)
an increase in changes in fair market value of strategic investments and net finance costs of $45,163,891,
(ix)
an increase in income taxes of $1,033,412
EBITDA
The EBITDA in 2020 was $43,824,533 compared to an EBITDA loss of $7,384,862 for 2019, representing an increase of 693% year-over-year. The increase in the EBITDA in 2020 compared to 2019 is due to the increase in net earnings and comprehensive income of $50,939,520, offset by a decrease in depreciation on property and equipment of $105,717, an increase in depreciation on right-of-use assets of $48,552, an increase in amortization of intangible assets of $7,057, a decrease in finance charges of $713,431 and an increase in income taxes of $1,033,412.
Adjusted EBITDA in 2020 was $48,069,141 compared to an Adjusted EBITDA loss of $4,845,524 for 2019. The increase of $52,914,665 in the Adjusted EBITDA in 2020 is attributable to an increase in EBITDA of $51,209,395, an increase of $4,072,801 in share-based payments, a decrease in inventory write-off of $386,121, and a decrease in equipment write-off of $1,981,410.
The Modified EBITDA in 2020 was $3,442,443 compared to a Modified EBITDA loss of $5,021,761 for 2019, representing an increase of 169%. The increase in the Modified EBITDA in 2020 is attributable to the increase as mentioned above in the Adjusted EBITDA of $52,914,665 and an increase in chance of fair value of investments of $44,450,461.
Liquidity
As at December 31, 2020, the Company has cash and cash equivalents of $18,104,899. In addition, the accounts payable and accrued liabilities of $4,708,051 are payable within 12 months. The Company expects that its cash position will be able to finance its operations for the foreseeable future.
On November 3, 2020, the Company closed a bought-deal short form prospectus offering of 3,354,550 units at a price of $3.60 per unit for aggregate gross proceeds to the Company of $12,076,380, including the full exercise of the over-allotment option. In connection with the offering, the Company paid $1,934,154 in cash and issued 191,414 compensation options. Each compensation option entitles the holder thereof to purchase one unit at a price of $3.60 until November 10, 2022. Each unit is comprised of one common share of the Company and one-half of one common share purchase warrant of the company. Each warrant entitles the holder to purchase one additional common share at an exercise price of $4.50 for a period of 24 months.
At December 31, 2020, there have not been any material uses of the proceeds received from the offering.
About PyroGenesis Canada Inc.
PyroGenesis Canada Inc., a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and products. The Company provides its engineering and manufacturing expertise and its turnkey process equipment packages to customers in the defense, metallurgical, mining, advanced materials (including 3D printing), and environmental industries. With a team of experienced engineers, scientists and technicians working out of its Montreal office and its 3,800 m 2 and 2,940 m 2 manufacturing facilities, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The Company’s core competencies allow PyroGenesis to provide innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified. For more information, please visit www.pyrogenesis.com .
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or atwww.sec.gov.Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as requiredby applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the NASDAQ Stock Market, LLC accepts responsibility for the adequacy or accuracy of this press release.
Posted by AGORACOM-JC
at 6:40 PM on Wednesday, March 31st, 2021
Valeo secured the Canadian rights to Enerzair® Breezhaler® and Atectura® Breezhaler®, two new innovative Asthma therapies
Q1-21 net revenues of $1.9 million , up 11 % vs Q1-20
Frederic Fasano appointed as President and Chief Operating Officer
Redesca® and Redesca HP® receive Health Canada approval, launching in Q3
Hesperco™ capsules at the core of a Montreal Heart Institute’s COVID-19 study
MONTREAL , March 31, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2021 .
“Our first quarter has laid the foundation for a transformational year for Valeo. The commercialization agreement with Novartis Canada positions Valeo as one of the leading Canadian companies in respirology . We are excited about the opportunity to enter the growing asthma market with two innovative drugs, Enerzair® Breezhaler® and Atectura® Breezhaler®. The Canadian asthma market exceeds $700 million annually 1 and is expected to growth at 2-3% per year over the next ten years. We expect combined peak sales of these two new drugs to exceed $100 million annually.”, said Steve Saviuk , Valeo’s CEO. “With the coming launch of Redesca, our low-molecular-weight-heparin biosimilar, and the Montreal Institute of Cardiology’s ongoing Covid-19 clinical trial involving Hesperco capsules, 2021 marks a turning point in Valeo’s history”.
Commenting on the first quarter 2021 results, Luc Mainville , Senior Vice-President and Chief Financial Officer said, “Our net revenues for the quarter continued to grow and reflected the addition of several products during the latter part of our 2020 fiscal year. Our first quarter results were impacted by calendar year-end slowdown of the pharma sector as well as increase in operating expenses to support our growth initiatives. Sales & Marketing expenses increased due to the addition of Redesca’s national key account manager team. Our General & Administrative expenses also increased during the quarter as a result of the addition to the Head Office personnel and increased marketing related expenses. We expect additional investments to be made in 2021 as we prepare ourselves to support the Canadian commercialization of Enerzair® Breezhaler® and Atectura® Breezhaler® already approved by Health Canada and available for sale. We anticipate strong revenue growth in the second quarter of fiscal 2021 and accelerated growth in the coming quarters as a result of these product additions which will derive incremental margins and drive our profitability going forward.
References:
IQVIA CDH June 2020
First Quarter 2021 Financial Results and Highlights
Net revenues were $1.9 million for the quarter ended January 31, 2021 compared to $1.7 million for the quarter ended January 31, 2020 . The increase over the previous comparable period is mainly due to the Onstryv revenue growth and the launch of new products such as Ametop, Yondelis and the launch of Sodium Ethacrynate in the U.S. ;
Net loss of $1.7 million for the quarter ended January 31, 2021 compared to $1.1 million for the quarter ended January 31, 2020 . The increase in net loss is a result of the increase in Sales & Marketing and General & Administrative expenses required to position Valeo for solid revenue growth in 2021; and
Adjusted EBITDA loss of $1.1 million for the quarter ended January 31, 2021 compared to $0.9 million for the quarter ended January 31, 2020 .
First Quarter 2021 Business and Product Highlights
In January 2021 , the Company received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of Redesca® and Redesca® HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ);
In January 2021 , the Company appointed Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer. Mr. Fasano is a seasoned Canadian and international pharma executive having lead pharmaceutical organizations in Europe and Canada. His addition augments Valeo’s senior leadership team and support expansion of Valeo’s commercial activities;
In December 2020 , the Company announced that its shares were eligible for electronic clearing and settlement in the U.S. through the Depository Trust Company (“DTC”);
In December 2020 , the Company received a Notice of Compliance from Health Canada for its Redesca and Redesca HP low molecular weight heparin (“LMWH”) biosimilars; and
In November 2020 , the Company received a Notice of Compliance from Health Canada granting market authorization for Amikacin and commenced shipments of Ethacrynate Sodium in the U.S. market.
Subsequent Events
In March 2021 , the Company entered into a Commercial and Supply Agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian commercialization by Valeo of two innovative asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate), glycopyrronium (as bromide) and mometasone furoate) and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate); and
In February 2021 , the Company announced that Hesperco™ capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute’s (“MHI”) clinical trial, “The Hesperidin Coronavirus Study”;
Q1 2021 Webcast and Conference Call
Valeo will host a conference call to discuss the first quarter 2021 results and highlights on Thursday April 1, 2021 at 8.30am (EST) . The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. An audio replay of the call will be available. The numbers to access the audio replay are 1-855-859-2056 and 416-849-0833 using the following access code (5555964).
A live audio webcast of the conference call will be available via:
Valeo Pharma’s financial statements and Management’s Discussion and Analysis for the three-month ended January 31, 2021 are available on SEDAR at www.sedar.com
About Valeo Pharma
Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.
Forward Looking Statements
This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Posted by AGORACOM-JC
at 8:51 AM on Wednesday, March 31st, 2021
Received up to $2 Million in funding from the Ontario Together Fund to accelerate commercial production of the BioCloud units.
To date $1.2 Million has been received from the Ontario Together Fund. In order to receive the final balance of $800,000 certain conditions are required to be met, which includes the increase of manufacturing capacity to 20,000 units per month.
Confirming that it has met the conditions precedent for the final $800,000 in funding
TORONTO , March 31, 2021 – Kontrol Technologies Corp.(CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) (” Kontrol Technologies ” or ” Kontrol ” or ” Company “) is pleased to provide an update on its manufacturing capacity as it relates to various milestones for the Ontario Together Fund.
As a follow up to the press release dated February 4 th , 2021, CEM Specialties Inc. (” CEMSI “), a wholly owned subsidiary of Kontrol Technologies, received up to $2 Million in funding from the Ontario Together Fund to accelerate commercial production of the BioCloud units. To date $1.2 Million has been received from the Ontario Together Fund. In order to receive the final balance of $800,000 certain conditions are required to be met, which includes the increase of manufacturing capacity to 20,000 units per month.
The Company will deliver a final package to the Ontario Together Fund in the next week, confirming that it has met the conditions precedent for the final $800,000 in funding, including the required manufacturing capacity. Manufacturing capacity is the ability to manufacture a certain number of units per month and is not a sales forecast. The final $800,000 funding balance is issued at the discretion of the Ontario Together Fund following the Company’s submission.
“As we initiated commercial production, we have made continuous improvements to the manufacturing of BioCloud,” says Paul Ghezzi , CEO of Kontrol. “Some of these improvements relate to a reduction in sizing of internal systems, reduction of electronic boards and overall streamlining of installation. This is part of the normal process of moving from individual prototypes to commercial production. We have done so in a short period of time with great effort from the entire team.”
“We have made great progress with BioCloud manufacturing,” says Jeff Stewart , CEO of OES Inc. “Through our internal capacity and the addition of manufacturing capacity with our Ontario based strategic manufacturing partners we are pleased to be able to deliver up to 20,000 units per month in manufacturing capacity.”
Global Supply Chain
Currently the global supply chain for the majority of components used in the manufacturing of BioCloud appears to be stabilizing. However, lead times on electronic components and semi-conductors, which are subject to competition from the automotive and mobile industry, have been a challenge. The Company reviews the global supply chain with its manufacturing partner OES Inc. on a routine basis. The Company has no control over potential delays and lead times in the global supply chain.
“I am proud of our team which has worked tirelessly to design and develop a technology with the primary goal of assisting in the reduction of transmittance of the SARS-CoV-2 virus and its variants through earlier detection,” says Gary Saunders , President of Kontrol BioCloud. “In addition to vaccines, technologies which can provide early alerting systems are important to help us create safer spaces and get back to normal across the global economy.”
BioCloud Reagent and Antibodies
The BioCloud unit operates to detect SARS-CoV-2, and other viruses, bacteria and fungi from the air through the use of continuous air sampling and a biological response process. The primary component which makes up the BioCloud proprietary reagent is a specifically formulated combination of antibodies. The antibodies, which are purchased from third party manufacturers, are combined, and tested by independent labs for the reaction to and detection of the SARS-CoV-2 virus.
The Company’s patented antibody cooling chamber utilizes a Peltier element technology to ensure accurate and controlled temperatures are maintained for the entire life cycle of the antibodies. In addition, the Company deploys refrigerated packaging to ensure a specific temperature range is maintained during transportation and shipping of its reagent and antibodies.
The Company continues to review various antibodies from third party manufacturers with the goal to reduce the costs of BioCloud consumables and create a large supply pool to choose from as part of its overall supply chain management.
Posted by AGORACOM-JC
at 8:44 AM on Wednesday, March 31st, 2021
Announce the closing of its previously announced acquisition on February 23, 2021 of all of the issued and outstanding shares of the entities that collectively comprise the business of 180 Smoke
Vaughan, Ontario–(March 31, 2021) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“), an established Canadian cannabis and vape retailer, is pleased to announce the closing of its previously announced acquisition on February 23, 2021 of all of the issued and outstanding shares of the entities that collectively comprise the business of 180 Smoke (“180 Smoke“), a dominant vape retailer in Canada. On March 30, 2021, the Company purchased all of the shares of 180 Smoke (the “Acquisition“) from CRHC Holdings Corp. (the “Seller“), on a cash-free basis (after post-closing adjustments), for nominal consideration. Additionally, the Company secured a strategic institutional investor to lead the acquisition of all the existing debt of 180 Smoke owing to an affiliate of the Seller.
Dan Pelchovitz, President & CEO of Spyder, commented, “We are extremely excited to welcome 180 Smoke to the Spyder team, which undoubtedly strengthens our management and operating teams bringing strong retail processes and expertise to Spyder. The acquisition of 180 Smoke significantly accelerates the development of Spyder’s cannabis and vape retail growth strategy, providing access to an iconic brand name, an established platform, and a loyal customer base. We are excited by the prospects ahead of us and executing on our immediate cannabis retail expansion plans in Ontario.”
Transaction Highlights
180 Smoke is a leading Canadian vape product retailer that has been widely regarded as the gold standard for vape store operations and customer service. 180 Smoke sells high-quality e-cigarettes, vaporizers and other nicotine-related products.
The Acquisition is expected to immediately increase Spyder’s consolidated revenue with the addition of 180 Smoke’s nicotine vape sales, franchise revenue and other wholesale and distribution revenue which generated approximately $12.9 million in unaudited net revenue with gross margins of 50% during the year ended December 31, 2020.
180 Smoke has a team of 91 employees who will continue to operate 180 Smoke’s 18 brick and mortar vape retail locations, 8 franchises, and its corporate head office and distribution warehouse, following the closing of the Acquisition.
180 Smoke’s current customer base includes 92,481 in-store accounts, 98,052 online accounts, as well as 235 specialty wholesale vape B2B accounts.
Immediately after closing, Spyder expects to integrate its 2 brick and mortar vape retail stores with those of 180 Smoke’s to leverage the acquired know-how and intellectual property, including retail store design and layout, standard operating procedures, administrative systems and customer support, human resources and staff training, and accounting.
Synergies are also expected between 180 Smoke’s existing customer base with Spyder’s cannabis business.
Spyder will have the ability to utilize its wholly-owned subsidiary’s Retail Operator License issued by the Alcohol and Gaming Commission of Ontario (AGCO) to convert some of 180 Smoke’s existing vape retail locations to licensed cannabis dispensaries by obtaining a Retail Store Authorization from the AGCO for such store.
Posted by AGORACOM-JC
at 7:49 AM on Wednesday, March 31st, 2021
Announced the Company has partnered with Data Clymer to provide Loop’s real-time data collection, insights and engagement solutions to Data Clymer’s growing list of clients, including its leading clients in professional sports and live entertainment.
Data Clymer has significant experience in live sports and entertainment, including clients in Major League Baseball and the National Football League that are now demanding more flexibility with their data and analytics systems.
VANCOUVER, British Columbia., March 31, 2021 — (MTRX:TSXV; RACMF:OTCQB) (the “Company” or “Loop”), is pleased to announce the Company has partnered with Data Clymer to provide Loop’s real-time data collection, insights and engagement solutions to Data Clymer’s growing list of clients, including its leading clients in professional sports and live entertainment.
PARTNERSHIP WITH DATA CLYMER SOLVES MAJOR REAL-TIME DATA ANALYTICS ISSUES FOR PRO SPORTS TEAMS, LEAGUES, STADIUMS, AND VENUE HOSTS BY PROVIDING ACCESS TO LOOP INSIGHTS SOLUTIONS
Data Clymer has significant experience in live sports and entertainment, including clients in Major League Baseball and the National Football League that are now demanding more flexibility with their data and analytics systems. Specifically, current “black-box” customer data platforms are creating bottlenecks for organizations, leading to a poor customer experience including:
Information stuck in data silos
Slow “time-to-insights”
When integrated with Data Clymer’s existing technologies, Loop Insights will provide its solution for professional sports teams, leagues, stadiums, and venue operators seeking to aggregate and action the countless data points generated by today’s live sports and entertainment venues.
Aron Clymer, Founder & CEO of Data Clymer stated, “As a leader in the business intelligence and data space, Data Clymer prides itself in guiding organizations to leverage the full value of their data. We are confident Loop’s products and services will greatly enhance the abilities of our clients in live sports and entertainment as they seek to unify and aggregate their data points to provide a revolutionary in-stadium experience.”
Data Clymer is a full-service data consulting firm that implements technologies such as Snowflake, Matillion, Fivetran, Looker, Sigma, and Tableau, and now includes Loop’s real-time data collection, insights, and engagement solutions.
Loop Insights CEO Rob Anson stated, “The importance and validation of this partnership can best be understood by a recent testimonial of the San Francisco Giants who stated ‘Our partnership with Data Clymer is the single best decision we made in our efforts to ramp up our analytics efforts’. This key partnership puts Loop alongside a very elite list of Data Clymer partners that includes top tech solution providers such as Snowflake, Looker, Tableau and many others. Loop’s ability to provide real-time interoperable POS data connectivity for venue owners and operators has brought a great deal of interest within the sports and entertainment industry as of late. With this Data Clymer partnership, we anticipate Loop will benefit from and experience an entirely new level of growth in revenue and scale within the sports and entertainment vertical.”
DATA CLYMER PARTNERSHIP WILL BOLSTER OFFERINGS IN USD$4.6-BILLION GLOBAL SMART STADIUM MARKET
According to Markets and Markets, the global smart stadium market grew to USD$4.6-billion in 2018 and is expected to reach USD$12.5-billion by 2023, representing a Compound Annual Growth Rate (CAGR) of 22.1%. Loop’s data solutions provide venue hosts with a means of aggregating the most important customer information available in order to generate actionable insights, engage with their customers in real-time, and optimize its operations.
The growth of the smart stadium market has been driven by the advancements in stadium technologies, which have improved vastly to provide owners with countless data points, including information accrued from tickets, concession sales, retail transactions, parking, accommodations, and more services offered in association with live events.
Through Loop’s data solutions, venues are able to aggregate these siloed and disparate data sets into one complete dashboard, providing hosts with actionable insights that can be used to engage in real-time with their customers to improve the overall fan experience.
About Data Clymer Data Clymer ( www.dataclymer.com ) is a boutique consulting firm specializing in data culture transformation. The company’s proven methodology includes full data warehouse stack implementation, data democratization, custom training, and analytics to enable data-driven decisions across the organization.
About Loop Insights Loop Insights Inc. ( www.loopinsights.ca ) is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative automated marketing and contactless payment solutions built on artificial intelligence (“AI”) to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network.
This news release contains certain statements that constitute forward-looking statements or information, including statements regarding Loop’s business and technology; the ability of Loop to engage with industry participants to achieve its goals; the development of Loop’s technology; and the viability of Loop’s business model. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, competition from other industry participants, stock market volatility, and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated, or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
Tags: AI, Amazon, artificial intelligence, Big data, covid19, NCAA, small cap Posted in Loop Insights Inc. | Comments Off on Loop Insights $MTRX $RACMF Partners with Data Clymer to Provide Loop’s Real-Time Data Solutions To Its Top-Tier Client List Including the National Football League and Major League Baseball $AT.ca $QTRH.ca $SNSR $BSQR $PTS.ca